Valneva SE (VALN) Net Income towards Common Stockholders (2021 - 2026)
Valneva SE's (VALN) quarterly Net Income towards Common Stockholders came in at -$27.7 million in Q1 2026, down 342.51% year-on-year from $11.4 million in Q1 2025, and up 52.41% quarter-over-quarter from -$58.3 million in Q4 2025.
Valneva SE (VALN) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends
Valneva SE has disclosed Net Income towards Common Stockholders across 6 years of filings, most recently posting -$27.7 million for Q1 2026.
- Net Income towards Common Stockholders for Q1 2026 came in at -$27.7 million, down 342.51% year-over-year; the trailing twelve-month figure through Mar 2026 was -$141.7 million (down 116.52% YoY), and the FY2025 annual result was -$134.1 million, down 1041.56% from the prior year.
- Net Income towards Common Stockholders came in at -$27.7 million for Q1 2026 at Valneva SE, up from -$58.3 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $74.1 million in Q1 2024 to a low of -$151.4 million in Q2 2022.
- The 5-year median for Net Income towards Common Stockholders is -$23.2 million (2024), against an average of -$22.7 million.
- Across the five-year window, Net Income towards Common Stockholders soared 516.53% in 2024 and sank 342.51% in 2026, its largest moves.
- Valneva SE's Net Income towards Common Stockholders stood at -$57.5 million in 2022, then surged by 53.39% to -$26.8 million in 2023, then advanced by 16.72% to -$22.3 million in 2024, then slumped by 161.21% to -$58.3 million in 2025, then jumped by 52.41% to -$27.7 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$27.7 million (Q1 2026), -$58.3 million (Q4 2025), and -$43.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -56.48 Mn |
| 10 | Valneva SE | 167.33 Mn | 44.10 Mn | 5.08 Mn | -27.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -27.74 Mn |
| Dec 31, 2025 | -58.29 Mn |
| Sep 30, 2025 | -43.39 Mn |
| Jun 30, 2025 | -12.30 Mn |
| Mar 31, 2025 | -6.27 Mn |
| Dec 31, 2024 | -22.32 Mn |
| Sep 30, 2024 | -13.67 Mn |
| Jun 30, 2024 | -23.20 Mn |
| Mar 31, 2024 | 74.10 Mn |
| Dec 31, 2023 | -26.80 Mn |
| Sep 30, 2023 | -24.18 Mn |
| Jun 30, 2023 | -20.03 Mn |
| Mar 31, 2023 | -17.79 Mn |
| Dec 31, 2022 | -57.49 Mn |
| Sep 30, 2022 | 72.80 Mn |
| Jun 30, 2022 | -151.43 Mn |
| Mar 31, 2022 | -28.10 Mn |
| Dec 31, 2021 | 193.58 Mn |
| Sep 30, 2021 | -185.83 Mn |
| Jun 30, 2021 | -68.19 Mn |